Solid pseudopapillary tumor of the pancreas

Last revised by Henry Knipe on 4 Mar 2024

Solid pseudopapillary tumors of the pancreas are rare and usually benign pancreatic cystic neoplasms that are most commonly seen in young females.  

The tumor has been referred to with multiple different names, including:

  • solid pseudopapillary tumor (SPT) of the pancreas

  • solid pseudopapillary neoplasm (SPN)

  • solid pseudopapillary epithelial neoplasm (SPEN)

  • papillary cystic neoplasm of the pancreas

  • Hamoudi tumor

  • Gruber-Frantz tumor (or just Frantz tumor)

They are rare and thought to account for 1-2% of exocrine pancreatic tumors. They tend to present in young non-White females around the 2nd and 3rd decades of life (the "daughter" tumor) 10.

Most patients are asymptomatic at diagnosis. They may occasionally present with a gradually enlarging abdominal mass or vague abdominal pain.

The tumors frequently contain varying amounts of necrosis, hemorrhage, and cystic change. Lesions can be large at the time of diagnosis (median size ~8 cm) 2.

There is a greater predilection to occur at the pancreatic tail.

Large well-defined mass with heterogeneous appearances, due to its solid and cystic composition.

Usually seen as a well-encapsulated lesion with varying solid and cystic components owing to hemorrhagic degeneration. Following IV contrast administration, enhancing solid areas are typically noted peripherally, whereas cystic spaces are usually more centrally located. Calcifications and enhancing solid areas may be present at the periphery of the mass.

Typically demonstrates a well-defined lesion. May show a pure solid consistency in ~80% of cases 6.

Reported signal characteristics include:

  • T1: low to heterogeneous signal intensity 1,6

  • T2: heterogeneous to high signal intensity 1,6

  • T1 C+ (Gd): can show early heterogeneous and slowly progressive enhancement 11

While most lesions are benign, ~15% can be malignant. Complete resection is associated with long-term survival even in the presence of metastatic disease.

It was first described by renowned American surgical pathologist, Virginia K Frantz (1896-1967) 9 et al. in 1959, hence the historical name "Frantz tumor" 4,5.

ADVERTISEMENT: Supporters see fewer/no ads